Shopping Cart
- Remove All
Your shopping cart is currently empty
PFE-360
Catalog No. T16512Cas No. 1527475-61-1
Alias PF-06685360
PFE-360 (PF-06685360) is a potent and selective inhibitor of LRRK2 kinase, with an in vivo IC50 of 2.3 nM.
PFE-360
Catalog No. T16512Alias PF-06685360Cas No. 1527475-61-1
PFE-360 (PF-06685360) is a potent and selective inhibitor of LRRK2 kinase, with an in vivo IC50 of 2.3 nM.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $68 | In Stock | |
| 2 mg | $98 | In Stock | |
| 5 mg | $172 | In Stock | |
| 10 mg | $239 | In Stock | |
| 25 mg | $488 | In Stock | |
| 50 mg | $716 | In Stock | |
| 100 mg | $987 | In Stock | |
| 500 mg | $1,980 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "PFE-360"
GNE-7915
GNE7915
T19451351761-44-8
GNE-7915 is a highly potent, selective and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) inhibitor.
- $39
Size
QTY
LRRK2 inhibitor 1
T118781802525-61-6In house
LRRK2 inhibitor 1 is a selective and potent LRRK2 inhibitor with an IC50 of 13 nM.LRRK2 inhibitor 1 inhibits DCLK1 kinase with an IC50 value of 2.61 nM.
- $68
Size
QTY
LRRK2-IN-7
T731762307277-93-4In house
LRRK2-IN-7 is a selective, CNS permeable and potent LRRK2 kinase inhibitor (IC50: 0.9 nM) for the study of Parkinson's disease.
- $239
Size
QTY
GSK2578215A
T22401285515-21-0
GSK2578215A is a potent and selective LRRK2 kinase inhibitor.
- $29
Size
QTY
GNE0877
GNE-0877, GNE 0877
T60311374828-69-9
GNE0877 (GNE 0877) is a highly effective and specific leucine-rich repeat kinase 2 (LRRK2) inhibitor (Ki: 0.7 nM).
- $39
Size
QTY
LRRK2-IN-1
Cited
T22461234480-84-2
LRRK2-IN-1 is an effective and selective LRRK2 inhibitor.
- $60
Size
QTY
CitedGNE-9605
T17701536200-31-3
GNE-9605 is a highly effective, specifical, and brain-penetrant LRRK2 inhibitor (IC50: 19 nM).
- $32
Size
QTY
CZC-25146
CHEMBL2397014
T30531191911-26-8
CZC-25146 (CHEMBL2397014) is an effective, specific and metabolically stable LRRK2 inhibitor with IC50 of 4.76/6.87 nM for wild-type LRRK2(Leucine-rich repeat kinase-2) and G2019S LRRK2, respectively.
- $39
Size
QTY
CCG-1423 Cited
CCG1423
T2014285986-88-1
CCG-1423, a selective RhoA pathway inhibitor, suppresses SRF-mediated transcription.
- $32
Size
QTY
CitedEB-42486
T399722390475-81-5
EB-42486 is an effective and highly selective inhibitor of G2019S-LRRK2 with an IC50 < 0.2 nM.
- $64
Size
QTY
CZC-54252 hydrochloride
T392021784253-05-9
CZC-54252 hydrochloride is a selective inhibitor of LRRK2 with IC50s of 1.85 nM and 1.28 nM for wild-type and G2019S LRRK2. CZC-54252 hydrochloride has a neuroprotective activity and attenuates G2019S LRRK2-induced human neuronal injury with an EC50 of 1 nM.
- $44
Size
QTY
Select Batch
Purity:99.73%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | PFE-360 (PF-06685360) is a potent and selective inhibitor of LRRK2 kinase, with an in vivo IC50 of 2.3 nM. |
| Targets&IC50 | LRRK2:2.3 nM (IC50) |
| In vivo | PFE-360 (4 mg/kg and 7.5 mg/kg, orally, BID, 10-12 weeks) treatment effectively reduces the LRRK2-pSer935/total LRRK2 ratio. It has no significant adverse effects[1]. |
| Alias | PF-06685360 |
| Molecular Weight | 308.34 |
| Formula | C16H16N6O |
| Cas No. | 1527475-61-1 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
| Solubility Information | DMSO: 3.08 mg/mL (10 mM), Sonication is recommended.  | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy PFE-360 | purchase PFE-360 | PFE-360 cost | order PFE-360 | PFE-360 chemical structure | PFE-360 in vivo | PFE-360 formula | PFE-360 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.